ProPharma Group Announces Acquisition of Southwood Research

March 11, 2019

ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Southwood Research.  Based in Buckinghamshire, United Kingdom, Southwood Research is a leading provider of pre-approval regulatory science services to the pharmaceutical and biotech industries.  “We are thrilled about our future as a part of ProPharma Group. The combination expands our global reach, as well as our ability to provide end-to-end services for our clients within regulatory affairs,” said Colin Wheeler, Southwood Research’s Managing Director.

This acquisition extends ProPharma Group’s highly specialized scientific regulatory affairs capabilities throughout the EU marketplace, while bolstering its regulatory affairs service portfolio from pre-clinical/pre-approval through post-approval.  “Southwood Research’s proven experience is pivotal throughout the developmental phases of a product’s lifecycle and has made them an invaluable partner to their growing roster of pharmaceutical and biotech clients.  We are excited to support the entire ProPharma Group organization as they expand their global presence and enhance their existing portfolio of services to better serve their customers,” said Michael Farah, Chairman of ProPharma and Partner at Linden Capital Partners.

ProPharma Group, a leading provider of compliance services, continues to expand its global presence, now with more than 1,100 employees across United States, Canada, Europe, Japan, and Australia.  “The addition of Southwood Research’s deep scientific expertise emphasizes ProPharma Group’s commitment to providing industry leading regulatory support to our clients.  ProPharma Group’s robust regulatory capabilities, bolstered by the recent additions of The Weinberg Group in the United States and now Southwood Research in the UK, represent a truly unique end-to-end global regulatory practice,” said Dawn Sherman, ProPharma Group’s CEO.

About ProPharma Group

ProPharma Group, a portfolio company of Linden Capital Partners, is an international, independent, single-source provider of comprehensive compliance services that span the entire lifecycle of pharmaceuticals, biologics, and medical devices.  ProPharma Group has more than 1,100 colleagues worldwide providing an unmatched variety of compliance related services including life science consulting, medical information, pharmacovigilance, and regulatory affairs.

 About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on investing in the healthcare industry.  Linden’s strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms across the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.

Company News

April 12, 2012

ProPharma Group, Inc. announces the opening of a new office in Southern California

Overland Park, Kansas – Carlsbad, California ProPharma Group is pleased to announce the opening of a new office in Carlsbad, California. This is another significant step for ProPharma Group and its'...

Read the Full Article

April 17, 2018

The Weinberg Group CEO to Speak at AIPPI’s International Convention on the Economy of Innovation

WASHINGTON, DC – April 17, 2018 – Matthew Weinberg, Chief Executive Officer of The Weinberg Group Inc., will be speaking at the International Association for the Protection of Intellectual Property’s...

Read the Full Article

August 16, 2013

Matthew Weinberg Writes for International Clinical Trials (ICT) Magazine

In this article CEO Matthew Weinberg discusses the downsides to self-auditing good clinical practice and the need smaller, more proactive audits, on the other hand, can provide a more intelligent...

Read the Full Article